Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer

Tamoxifen is the standard-of-care treatment for estrogen receptor-positive premenopausal breast cancer. We examined tamoxifen metabolism via blood metabolite concentrations and germline variations of CYP3A5, CYP2C9, CYP2C19 and CYP2D6 in 587 premenopausal patients (Asians, Middle Eastern Arabs, Cauc...

Full description

Bibliographic Details
Main Authors: Saladores, P. (Author), Mürdter, T. (Author), Eccles, Diana (Author), Chowbay, B. (Author), Zgheib, N.K (Author), Winter, S. (Author), Ganchev, B. (Author), Eccles, Bryony (Author), Gerty, Sue (Author), Tfayli, A. (Author), Lim, J.S.L (Author), Yap, Y.S (Author), Ng, R.C.H (Author), Wong, N.S (Author), Dent, R. (Author), Habbal, M.Z (Author), Schaeffeler, E. (Author), Eichelbaum, M. (Author), Schroth, W. (Author), Schwab, M. (Author), Brauch, H. (Author)
Format: Article
Language:English
Published: 2015.
Subjects:
Online Access:Get fulltext